Royapuram Parthasarathy Parameswari, Manikandamathavan Verasundaram M, Chandronitha Chandranayagam, Vasanthi Hannah R, Mohan Vasanth Kumar, Vijayakumar Venkataramanan, Shanmugam Rajeshkumar, Sekaran Saravanan, Unni Nair Balachandran, Chamundeeswari Duraipandian, Thyagarajan Sadras Panchatcharam
Centre for Transdisciplinary Research, Department of Pharmacology, Saveetha Dental College and Hospitals, SIMATS, Chennai, India.
Herbal and Indian Medicine Research Laboratory, Sri Ramachandra University, Chennai, India.
Front Bioeng Biotechnol. 2022 Apr 11;10:849441. doi: 10.3389/fbioe.2022.849441. eCollection 2022.
"Thamira parpam" (TP), a copper-based herbometallic oxide (copper (II) oxide) nanodrug has been used in Siddha medicine for centuries because of its anti-ulcerogenic property. However, the physicochemical properties and toxicity of TP still remain elusive. Rigorous clinical translation requires deciphering these vital properties. We have synthesized TP following a gold standard protocol in the traditional Siddha methodology. We assessed the size, phase, elemental constituents, and thermal stability of TP by SEM and TEM, XRD, EPR, and EDAX analyses, respectively. The results depicted the conversion of metallic copper into copper (II) oxide in the final stages of TP preparation and exhibited nanodimensions ranging between 10 and 50 nm. The XPS spectra revealed the presence of oxygen-deficient state and a carbonaceous coating was found on the surface of TP using TEM analysis. safety was studied in rat toxicity models by adopting OECD guidelines. Body weight changes, feed, and water intake were unaltered upon TP administration. Hematological, biochemical profiling, and histopathological findings also suggested its nontoxic nature with no abnormalities in major organs and its functions. Interestingly, we found that the metal toxicity could have been subdued because of the carbonaceous coating around the nanoparticle copper (II) oxide, confirming that the drug is safe at a low dose. Overall, our study has enlightened the safety of TP supporting the use of Siddha formulations.
“Thamira parpam”(TP)是一种铜基草药金属氧化物(氧化铜(II))纳米药物,由于其抗溃疡特性,在悉达医学中已使用了几个世纪。然而,TP的物理化学性质和毒性仍然难以捉摸。严格的临床转化需要解读这些关键特性。我们按照传统悉达方法中的金标准方案合成了TP。我们分别通过扫描电子显微镜(SEM)和透射电子显微镜(TEM)、X射线衍射(XRD)、电子顺磁共振(EPR)和能谱分析(EDAX)评估了TP的尺寸、相、元素组成和热稳定性。结果表明,在TP制备的最后阶段,金属铜转化为氧化铜(II),并且呈现出10至50纳米的纳米尺寸。X射线光电子能谱(XPS)光谱显示存在缺氧状态,并且通过TEM分析发现在TP表面有一层碳质涂层。采用经合组织(OECD)指南在大鼠毒性模型中研究了其安全性。给予TP后,体重变化、饲料和水摄入量未改变。血液学、生化分析和组织病理学结果也表明其无毒性质,主要器官及其功能无异常。有趣的是,我们发现由于纳米氧化铜(II)周围的碳质涂层,金属毒性可能已被抑制,这证实了该药物在低剂量下是安全的。总体而言,我们的研究揭示了TP的安全性,支持悉达配方的使用。